Online adaptive radiation therapy for various cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the feasibility of using online CBCT-guided adaptive radiation therapy on a standard Elekta linear accelerator for patients with prostate, cervical, bladder, lung, and head and neck cancers. The approach focuses on correcting geometric uncertainties and changes that occur between radiotherapy fractions, which could enhance the accuracy of treatment. By adapting the therapy in real-time, the study seeks to improve outcomes for patients who are currently treated on standard equipment. The research will involve patients aged 18 and older who meet specific eligibility criteria related to their cancer type and treatment plan.

Why it matters

Who can join: the full rules

General Inclusion Criteria:

* Patient, age ≥ 18 years, referred for a radiotherapy schedule as described in one of the cohorts.
* WHO performance score 0-3.
* Provision of signed, written and dated IC prior to any study specific procedures.

Specific inclusion criteria for prostate cohort:

* Accepted for radiotherapy of the prostate and pelvic lymph node areas.
* Pathology-proven prostate cancer.
* cT1-4
* cN1 on PSMA-PET/CT or pN1 based on node biopsy, SN-procedure or lymph node dissection.
* cM0 on PSMA-PET/CT (except for patients with M1a disease who are still considered for radiotherapy of the prostate and pelvic lymph node areas).

Specific inclusion criteria for cervical cohort:

* Accepted for radiotherapy of the cervix (with or without chemotherapy) and pelvic lymph node areas (25 fractions, followed by either a brachytherapy or external radiotherapy boost).
* Pathology-proven cervical cancer.
* FIGO IIA2, IB3 and \> 6cm, IIB-IVA or N+. Or other stage and unfit for surgery.
* cM0 or cM1 and accepted for locoregional radical (chemo)radiation in 25 fractions.

Specific inclusion criteria for bladder cohort:

* Accepted for radiotherapy of the bladder, either to the entire bladder or with a boost to the tumor area (with or without chemotherapy).
* Pathology-proven bladder carcinoma.
* cT1-4
* cN0 or cN1-2 after induction treatment (with or without lymph node dissection)

Specific inclusion criteria for lung cohort:

* Accepted for radiotherapy for lung cancer with lymph node metastases (with or without chemotherapy).
* Non-small cell lung cancer (either pathology proven or enough clinical suspicion to warrant radiotherapy to primary tumor and pathologic lymph nodes.
* cT1-4 and cN1-3.
* M0 or m1 and accepted for radical radiotherapy in 24 fractions of 1 or more lymph node metastases and a primary tumor and/or pulmonary metastases.

Specific inclusion criteria for head and neck cohort:

* Accepted for radiotherapy for head and neck cancer (with or without chemotherapy).
* Pathology-proven carcinoma of the pharynx, oral cavity or larynx.
* cT1-4
* cN0-3 and indication for elective neck radiation (either 1 or 2 sides).
* cM0

General Exclusion Criteria:

* Patients who are pregnant.

Specific for prostate cohort:

* Patients with a medical condition that severely compromises CBCT image quality (mainly hip prostheses).
* Severe lower urinary tract symptoms that could make the longer treatment time problematic (according to judgement of treating physician).

Specific for cervical cohort:

\- Patients with a medical condition that severely compromises CBCT image quality (mainly hip prostheses).

Specific for bladder cohort:

* Patients with a medical condition that severely compromises CBCT image quality (mainly hip prostheses).
* Severe lower urinary tract symptoms that could make the longer treatment time problematic (according to judgement of treating physician).

Specific for lung cohort:

\- Severe pulmonary complaints that could make the longer treatment time problematic (according to judgement of treating physician).

Specific for head and neck cohort:

* Severe complaints that could make the longer treatment time problematic (according to judgement of treating physician).
* Pulmonary fibrosis

Where it's running

• Antoni van Leeuwenhoek Hospital
  Amsterdam, Netherlands Recruiting

Study contacts

• Study coordinator: Evelien Schouten, MSc
• Email: ev.schouten@nki.nl
• Phone: +31205129140

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ImmunoPET imaging for solid tumors targeting Trop2

  This study is testing a new imaging method to see if it can help diagnose solid tumors like bladder and prostate cancer better than current methods.

  Recruiting Phase 2/3 RenJi Hospital · Shanghai · NCT06851663

• Investigating HER3-DXd for advanced solid tumors

  This study is testing a new drug called HER3-DXd to see if it can safely help people with advanced solid tumors like melanoma, head and neck cancer, and gastric cancer who have already tried other treatments.

  Recruiting at 92 sites Phase 2 Daiichi Sankyo · Duarte, California and 95 other locations · NCT06172478

• Validation of a blood test for early cancer detection and monitoring

  This study is testing a blood test to see if it can help find different types of cancer early and monitor patients after treatment.

  Recruiting at 3 sites Adela, Inc · Duarte, California and 16 other locations · NCT05366881

• Timing smartphone messages to boost activity for older cancer survivors with chronic pain

  This study tests whether sending short smartphone messages at certain times can increase physical activity in older cancer survivors with chronic pain.

  Recruiting Medical College of Wisconsin · Milwaukee, Wisconsin · NCT07227077

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Virtual exercise program to preserve function and prevent disability during chemotherapy

  This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.

  Recruiting at 29 sites Alliance for Clinical Trials in Oncology · Dublin, California and 29 other locations · NCT07059884

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.